MOLECULAR DOCKING AND DYNAMIC SIMULATION-BASED SCREENING IDENTIFIES INHIBITORS OF TARGETED SARS-COV-2 3CLPRO AND HUMAN ACE2

SARVESH GALGALE; RIDA ZAINAB; PRADEEP KUMAR A.; NITHYA M.; SUSHA D.; SAMEER SHARMA

doi:10.22159/ijap.2023v15i6.48782

Authors

SARVESH GALGALE Department of Bioinformatics, Bangalore, BioNome, India
RIDA ZAINAB Department of Biotechnology, Lahore College for Women University, Pakistan
PRADEEP KUMAR A. K. S. Rangasamy College of Technology, Thiruchengode, India
NITHYA M. K. S. Rangasamy College of Technology, Thiruchengode, India
SUSHA D. Department of Bioinformatics, Bangalore, BioNome, India
SAMEER SHARMA Department of Bioinformatics, Bangalore, BioNome, India https://orcid.org/0000-0002-3456-0263

DOI:

https://doi.org/10.22159/ijap.2023v15i6.48782

Keywords:

Omicron, COVID-19, SARS-CoV-2, ACE2, 3CLpro, MD simulation, Covid therapeutics

Abstract

Objective: Several genetic variations of Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) are continuously arising due to the uncontrolled dissemination of the virus during the pandemic. Omicron (B.1.1.529), the most prevalent variation of concern, has demonstrated extraordinary proliferation and pathogenicity and has emerged as the dominant variant as it has inflicted mass casualties worldwide.

Methods: Impeding the expression of 3CLpro, a coronavirus protease that is essential for digesting the RNA polyproteins, and the human angiotensin-converting enzyme 2 (ACE2) that serves as a receptor for the viral protein is identified as a competent therapeutic target. In the current study, human ACE2 and the viral 3CLpro complex was the target for the designing of novel drugs against the lethal virus. The docked complex was validated by Procheck, and the covid ligand library was investigated for its pharmacological efficacy using admetSAR 2.0. The molecular docking study was performed with the screened compounds obtained from the PubChem database against the docked protein complex.

Results: The ACE2 and 3CLpro proteins were docked together and the best docked complex was utilized for the analysis of the 1,87,419 compounds retreived from the PubChem COVID library, 18,642 compunds fulfilled the pharmacological screening and were appraised for docking with ACE2-3CLpro complex. The molecular docking results presented that the compounds 1-(4-fluorophenyl)-N'-(4-methylphenyl)propane-1,3-diamine (CID: 10038137) demonstrated significantly better binding (-18.7 kacl/mol) with favourable pharmacological properties and was therefore subjected to molecular dynamic simulations using Desmond Schrodinger 2019.2 GPU enabled package for 100 ns trajectory. The complex structure was observed to be stable after 15 ns and the average RMSD was observed to be ~0.65 nm. The complete binding energy of the complex with respect to MD simulation was-134.998+/-18.435 kj/mol which exposed that the inhibitor has a higher affinity towards the 3Clpro-ACE2 complex.

Conclusion: Consequently, this compound can be used to develop anti-covid medications to combat complications associated with Omicron infection.

Downloads

Download data is not yet available.

References

Widdowson MA, Bresee JS, Jernigan DB. The global threat of animal influenza viruses of zoonotic concern: then and now. J Infect Dis. 2017;216 Suppl 4:S493-8. doi: 10.1093/infdis/jix331, PMID 28934463.

Klemm C, Das E, Hartmann T. Swine flu and hype: a systematic review of media dramatization of the H1N1 influenza pandemic. J Risk Res. 2016;19(1):1-20. doi: 10.1080/13669877.2014.923029.

Jacob ST, Crozier I, Fischer WA II, Hewlett A, Kraft CS, Vega MA de L. Ebola virus disease. Nat Rev Dis Primers. 2020;6(1). doi: 10.1038/s41572-020-0147-3.

Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet. 2017;390(10107):2099-109. doi: 10.1016/S0140-6736(17)31450-2, PMID 28647173.

Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle east respiratory syndrome. Lancet. 2020;395(10229):1063-77. doi: 10.1016/S0140-6736(19)33221-0.

Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 omicron variant. J Med Virol. 2022;94(6):2376-83. doi: 10.1002/jmv.27643, PMID 35118687.

Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. doi: 10.1038/s41392-022-00997-x, PMID 35484110.

Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. doi: 10.1002/rmv.2381, PMID 35856385.

Ao D, Lan T, He X, Liu J, Chen L, Baptista Hon DT. SARS-CoV-2 omicron variant: immune escape and vaccine development. Med. 2022;3(1):e126. doi: 10.1002/mco2.126, PMID 35317190.

Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529)–variant of concern-molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021;25(24):8019-22. doi: 10.26355/eurrev_202112_27653, PMID 34982466.

Ettaboina SK, Nakkala K, Laddha KS. A mini-review on SARS-COVID-19-2 omicron variant (B.1.1.529). Sci Med J. 2021;3(4):399-406. doi: 10.28991/SciMedJ-2021-0304-10.

Liu Y, Liang C, Xin L, Ren X, Tian L, Ju X. The development of coronavirus 3C-like protease (3CLpro) inhibitors from 2010 to 2020. Eur J Med Chem. 2020;206:(112711). doi: 10.1016/j.ejmech.2020.112711, PMID 32810751.

Sisay M. 3CLpro inhibitors as a potential therapeutic option for COVID-19: available evidence and ongoing clinical trials. Pharmacol Res. 2020;156:(104779). doi: 10.1016/j.phrs.2020.104779, PMID 32247821.

Roe MK, Junod NA, Young AR, Beachboard DC, Stobart CC. Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. J Gen Virol. 2021;102(3). doi: 10.1099/jgv.0.001558, PMID 33507143.

Bhalla V, Blish CA, South AM. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens. 2021;35(10):935-9. doi: 10.1038/s41371-020-00459-3, PMID 33318644.

Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020;96(1137):403-7. doi: 10.1136/postgradmedj-2020-137935, PMID 32522846.

Chaudhry F, Lavandero S, Xie X, Sabharwal B, Zheng YY, Correa A. Manipulation of ACE2 expression in COVID-19. Open Heart. 2020;7(2):e001424. doi: 10.1136/openhrt-2020-001424, PMID 33443121.

Jia H, Neptune E, Cui H. Targeting ACE2 for COVID-19 therapy: opportunities and challenges. Am J Respir Cell Mol Biol. 2021;64(4):416-25. doi: 10.1165/rcmb.2020-0322PS, PMID 33296619.

Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648-54. doi: 10.1038/s41440-020-0455-8, PMID 32341442.

Alexpandi R, De Mesquita JF, Pandian SK, Ravi AV. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front Microbiol. 2020;11:1796. doi: 10.3389/fmicb.2020.01796, PMID 32793181.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102-9. doi: 10.1093/nar/gky1033, PMID 30371825.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202-13. doi: 10.1093/nar/gkv951, PMID 26400175.

Wang Y, Bryant SH, Cheng T, Wang J, Gindulyte A, Shoemaker BA. PubChem Bioassay: 2017 update. Nucleic Acids Res. 2017;45(D1):D955-63. doi: 10.1093/nar/gkw1118, PMID 27899599.

Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. Protein data bank (PDB): the single global macromolecular structure archive. Methods Mol Biol. 2017;1607:627-41. doi: 10.1007/978-1-4939-7000-1_26, PMID 28573592.

Jayasurya, Swathy, Susha, Sharma S. Molecular docking and investigation of Boswellia serrata phytocompounds as cancer therapeutics to target growth factor receptors: an in silico approach. Int J Appl Pharm. 2023;15(4):173-83. doi: 10.22159/ijap.2023v15i4.47833.

Laskowski RA, MacArthur MW, Thornton JM. PROCHECK: validation of protein-structure coordinates. In: International tables for crystallography. Chester, England: International Union of Crystallography; 2012. p. 684-7. doi: 10.1107/97809553602060000882.

Laskowski RA, Furnham N, Thornton JM. The Ramachandran plot and protein structure validation. In: Biomolecular forms and functions. Teaneck: World Scientific Publishing/Indian Institute of Science; 2013. p. 62-75.

Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255-78. doi: 10.1038/nprot.2016.169, PMID 28079879.

Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics. 2004;20(1):45-50. doi: 10.1093/bioinformatics/btg371, PMID 14693807.

Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on lipinski’s rule of five. J Comput Biol. 2020;27(9):1397-406. doi: 10.1089/cmb.2019.0323, PMID 32031890.

Karatzas E, Zamora JE, Athanasiadis E, Dellis D, Cournia Z, Spyrou GM. ChemBioServer 2.0: an advanced web server for filtering, clustering and networking of chemical compounds, facilitating both drug discovery and repurposing. Bioinformatics. 2020;36(8):2602-4. doi: 10.1093/bioinformatics/btz976, PMID 31913451.

Athanasiadis E, Cournia Z, Spyrou G. ChemBioServer: a web-based pipeline for filtering, clustering and visualization of chemical compounds used in drug discovery. Bioinformatics. 2012;28(22):3002-3. doi: 10.1093/bioinformatics/bts551, PMID 22962344.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243-50. doi: 10.1007/978-1-4939-2269-7_19, PMID 25618350.

Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z. AdmetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics. 2019;35(6):1067-9. doi: 10.1093/bioinformatics/bty707, PMID 30165565.

Tutorial Huey R, Morris GM, Forli S, Wustl Edu. Using auto dock 4 and auto dock vina with auto dock tools: a tutorial; 2012.

O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3(1):33. doi: 10.1186/1758-2946-3-33, PMID 21982300.

Wheeler G, Deng S, Toussaint N, Pushparajah K, Schnabel JA, Simpson JM. Virtual interaction and visualization of 3D medical imaging data with VTK and Unity. Healthc Technol Lett. 2018;5(5):148-53. doi: 10.1049/htl.2018.5064, PMID 30800321.

Gajula MNV, Kumar A, Ijaq J. Protocol for molecular dynamics simulations of proteins. Bio-Protocol. 2016;6(23). doi: 10.21769/BioProtoc.2051.

Bhowmik R, Roy S, Sengupta S, Sharma S. Biocomputational and pharmacological analysis of phytochemicals from Zingiber officinale (ginger), Allium sativum (garlic), and Murrayakoenigii (curry leaf) in contrast to type 2-diabetes. Int J App Pharm. 2021;13(5):280-6. doi: 10.22159/ijap.2021v13i5.42294.

Lopez Blanco JR, Aliaga JI, Quintana Orti ES, Chacon P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014;42:W271-6. doi: 10.1093/nar/gku339, PMID 24771341.

Bauer JA, Pavlovic J, Bauerova Hlinkova V. Normal mode analysis as a routine part of a structural investigation. Molecules. 2019;24(18):3293. doi: 10.3390/molecules24183293, PMID 31510014.

Lopez Blanco JR, Ramirez E, Garcia S, Chacon P. Imods: fast exploration of macromolecular collective motions. Biophys J. 2014;106(2):653a, doi: 10.1016/j.bpj.2013.11.3614.

PubChem.nih.gov.1-(4-fluorophenyl)-N′-(4-methylphenyl)propane-1,3-diamine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/10038137.

Calıca Utku A, Budak G, Karabay O, Guclu E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020;65(4):127-32. doi: 10.1177/0036933020949253, PMID 32807018.

Muller C, Hardt M, Schwudke D, Neuman BW, Pleschka S, Ziebuhr J. Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture. J Virol. 2018;92(4). doi: 10.1128/JVI.01463-17, PMID 29167338.

Sanjeeva P, Rao BS, Ramana PV, Raju CN, Rajani V, Prasad VK. Synthesis, characterization and molecular docking studies of novel 2-(5- bromobenzofuran-2-yl)-5-substitutedphenyl-1,3,4-oxadiazole derivatives. J Adv Sci Res. 2021;12(3):61-8. doi: 10.55218/JASR.202112309.

Semih B, Tugce Nur Y, Mehmet Sinan D, Serdal K, Burhan T, Fevzi A. Tyrosine kinase inhibitors and COVID-19. J Oncol Pharm Pract. 2020;26(8):2072-3. doi: 10.1177/1078155220967081, PMID 33081581.

Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110, PMID 32503877.

Bascı S, Ata N, Altuntas F, Yigenoglu TN, Dal MS, Korkmaz S. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020;26(7):1676-82. doi: 10.1177/1078155220953198, PMID 32854573.

Krishnan P, Bastow KF. Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives-eleutherin, α lapachone, and β lapachone∗. Biochem Pharmacol. 2000;60(9):1367-79. doi: 10.1016/s0006-2952(00)00437-8, PMID 11008131.

El-Kurdi B, Khatua B, Rood C, Snozek C, Cartin Ceba R, Singh VP. Mortality from coronavirus disease 2019 increases with unsaturated fat and may be reduced by early calcium and albumin supplementation. Gastroenterology. 2020;159(3):1015-1018.e4. doi: 10.1053/j.gastro.2020.05.057, PMID 32470338.